JP2005516067A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516067A5 JP2005516067A5 JP2003564042A JP2003564042A JP2005516067A5 JP 2005516067 A5 JP2005516067 A5 JP 2005516067A5 JP 2003564042 A JP2003564042 A JP 2003564042A JP 2003564042 A JP2003564042 A JP 2003564042A JP 2005516067 A5 JP2005516067 A5 JP 2005516067A5
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- compound
- different
- methyl
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- -1 hydroxy, methyl Chemical group 0.000 claims 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000001450 anions Chemical class 0.000 claims 3
- 229940006460 bromide ion Drugs 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229910052736 halogen Chemical group 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 206010040741 Sinus bradycardia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000013067 intermediate product Substances 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 239000013312 porous aromatic framework Substances 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 claims 1
- 230000001515 vagal effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10203741.8 | 2002-01-31 | ||
| DE10203741A DE10203741A1 (de) | 2002-01-31 | 2002-01-31 | Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| PCT/EP2003/000534 WO2003064419A1 (de) | 2002-01-31 | 2003-01-21 | Neue fluorencarbonsäureester, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2005516067A JP2005516067A (ja) | 2005-06-02 |
| JP2005516067A6 JP2005516067A6 (ja) | 2005-08-11 |
| JP2005516067A5 true JP2005516067A5 (enExample) | 2006-03-23 |
| JP4484522B2 JP4484522B2 (ja) | 2010-06-16 |
Family
ID=27588159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003564042A Expired - Lifetime JP4484522B2 (ja) | 2002-01-31 | 2003-01-21 | 新規フルオレンカルボン酸エステル、その製造方法及び薬物としてのその使用 |
Country Status (28)
| Country | Link |
|---|---|
| EP (2) | EP1561751A1 (enExample) |
| JP (1) | JP4484522B2 (enExample) |
| KR (1) | KR100950869B1 (enExample) |
| CN (1) | CN100348598C (enExample) |
| AR (1) | AR038379A1 (enExample) |
| AT (1) | ATE299880T1 (enExample) |
| AU (1) | AU2003210172C1 (enExample) |
| BR (1) | BR0307294A (enExample) |
| CA (1) | CA2472149C (enExample) |
| DE (2) | DE10203741A1 (enExample) |
| EA (1) | EA006966B1 (enExample) |
| EC (1) | ECSP045209A (enExample) |
| ES (1) | ES2245443T3 (enExample) |
| HR (1) | HRP20040690B1 (enExample) |
| IL (1) | IL162527A0 (enExample) |
| ME (1) | MEP43408A (enExample) |
| MX (1) | MXPA04007245A (enExample) |
| MY (1) | MY134582A (enExample) |
| NO (1) | NO328929B1 (enExample) |
| NZ (1) | NZ534784A (enExample) |
| PE (1) | PE20031029A1 (enExample) |
| PL (1) | PL209037B1 (enExample) |
| PT (1) | PT1472251E (enExample) |
| RS (1) | RS50918B (enExample) |
| TW (1) | TWI352077B (enExample) |
| UA (1) | UA78544C2 (enExample) |
| UY (1) | UY27633A1 (enExample) |
| WO (1) | WO2003064419A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007500148A (ja) * | 2003-07-28 | 2007-01-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅｉｖ阻害薬と新規な抗コリン作用薬とを含有する医薬品ならびに呼吸器疾患治療のための該医薬品の使用 |
| ATE420641T1 (de) * | 2003-07-28 | 2009-01-15 | Boehringer Ingelheim Int | Medikamente zur inhalation mit betamimetika und einem anticholinergikum |
| JP2007500147A (ja) * | 2003-07-28 | 2007-01-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ステロイド及びフルオレンカルボン酸エステルを含有する吸入用医薬品 |
| WO2005013994A1 (en) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising anticholinergics and a betamimetic |
| DE102004001607A1 (de) * | 2004-01-09 | 2005-08-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen auf der Basis von Scopin- oder Tropensäureestern mit EGFR-Kinase-Hemmern |
| JP2007523116A (ja) * | 2004-02-20 | 2007-08-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗コリン作用薬及びｐｅｇｓｕｎｅｒｃｅｐｔを基にした新規な医薬組成物 |
| US7507745B2 (en) * | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
| DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| US20060034776A1 (en) * | 2004-08-10 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Inhalable medicaments containing a new anticholinergic, corticosteroids, and betamimetics |
| DE102004038885A1 (de) * | 2004-08-10 | 2006-02-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum |
| ATE427108T1 (de) * | 2004-08-11 | 2009-04-15 | Boehringer Ingelheim Pharma | Anticholinergika enthaltende arzneimittel zur behandlung von krankheiten der ableitenden harnwege |
| DE102005001297A1 (de) * | 2005-01-12 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum |
| EP1855689A1 (en) * | 2005-02-16 | 2007-11-21 | Boehringer Ingelheim International GmbH | Pharmaceutical compositions comprising anticholinergics and etiprednol |
| EP1858554A2 (en) * | 2005-03-09 | 2007-11-28 | Boehringer Ingelheim International GmbH | New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors |
| EP1893203A2 (en) * | 2005-05-31 | 2008-03-05 | Boehringer Ingelheim International GmbH | Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor |
| DE102005030733A1 (de) | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
| US7423146B2 (en) | 2005-11-09 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones |
| CA2660186A1 (en) | 2006-08-07 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of respiratory diseases |
| PE20080610A1 (es) | 2006-08-22 | 2008-07-15 | Boehringer Ingelheim Int | Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos |
| EP1925296A1 (de) * | 2006-11-22 | 2008-05-28 | Boehringer Ingelheim Pharma GmbH & Co. KG | Stabile Pulverformulierung enthaltend ein neues Anticholinergikum |
| EP1997819A1 (de) * | 2007-05-25 | 2008-12-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Herstellung von Scopinestern |
| ES2569359T3 (es) | 2007-07-06 | 2016-05-10 | Vectura Delivery Devices Limited | Inhalador |
| CA2688669A1 (en) * | 2007-07-18 | 2009-01-22 | Boehringer Ingelheim International Gmbh | New combinations for the treatment of respiratory diseases |
| EP2082771A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
| EP2082766A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Blister Strip Coil Forming |
| EP2082767A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
| EP2082772A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
| EP2082768A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
| EP2093219A1 (de) | 2008-02-22 | 2009-08-26 | Boehringer Ingelheim International Gmbh | Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel |
| GB0918450D0 (en) | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
| CN102876318B (zh) * | 2012-09-28 | 2014-07-16 | 宁波大学 | 一种芴羧酸酯荧光材料及其制备方法 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CA3078232A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of dux4 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2221828A (en) * | 1936-04-25 | 1940-11-19 | Merck & Co Inc | Esters of amino alcohols with 9-hydroxyfluorene-9-carboxylic acid and processes for their production |
| DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
-
2002
- 2002-01-31 DE DE10203741A patent/DE10203741A1/de not_active Withdrawn
-
2003
- 2003-01-21 JP JP2003564042A patent/JP4484522B2/ja not_active Expired - Lifetime
- 2003-01-21 CN CNB038030004A patent/CN100348598C/zh not_active Expired - Fee Related
- 2003-01-21 BR BR0307294-0A patent/BR0307294A/pt not_active Application Discontinuation
- 2003-01-21 RS YUP-656/04A patent/RS50918B/sr unknown
- 2003-01-21 HR HRP20040690AA patent/HRP20040690B1/xx not_active IP Right Cessation
- 2003-01-21 ME MEP-434/08A patent/MEP43408A/xx unknown
- 2003-01-21 EP EP05004525A patent/EP1561751A1/de not_active Withdrawn
- 2003-01-21 PT PT03734600T patent/PT1472251E/pt unknown
- 2003-01-21 MX MXPA04007245A patent/MXPA04007245A/es active IP Right Grant
- 2003-01-21 CA CA2472149A patent/CA2472149C/en not_active Expired - Fee Related
- 2003-01-21 IL IL16252703A patent/IL162527A0/xx not_active IP Right Cessation
- 2003-01-21 AT AT03734600T patent/ATE299880T1/de active
- 2003-01-21 ES ES03734600T patent/ES2245443T3/es not_active Expired - Lifetime
- 2003-01-21 DE DE50300813T patent/DE50300813D1/de not_active Expired - Lifetime
- 2003-01-21 EA EA200400878A patent/EA006966B1/ru not_active IP Right Cessation
- 2003-01-21 UA UA20040807067A patent/UA78544C2/uk unknown
- 2003-01-21 NZ NZ534784A patent/NZ534784A/en not_active IP Right Cessation
- 2003-01-21 KR KR1020047011881A patent/KR100950869B1/ko not_active Expired - Fee Related
- 2003-01-21 EP EP03734600A patent/EP1472251B1/de not_active Expired - Lifetime
- 2003-01-21 AU AU2003210172A patent/AU2003210172C1/en not_active Ceased
- 2003-01-21 WO PCT/EP2003/000534 patent/WO2003064419A1/de not_active Ceased
- 2003-01-21 PL PL369396A patent/PL209037B1/pl unknown
- 2003-01-29 TW TW092101968A patent/TWI352077B/zh active
- 2003-01-29 MY MYPI20030303A patent/MY134582A/en unknown
- 2003-01-29 PE PE2003000092A patent/PE20031029A1/es not_active Application Discontinuation
- 2003-01-30 UY UY27633A patent/UY27633A1/es not_active Application Discontinuation
- 2003-01-31 AR ARP030100288A patent/AR038379A1/es not_active Application Discontinuation
-
2004
- 2004-07-28 EC EC2004005209A patent/ECSP045209A/es unknown
- 2004-08-30 NO NO20043612A patent/NO328929B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516067A5 (enExample) | ||
| JP2005525322A5 (enExample) | ||
| JP2005525323A5 (enExample) | ||
| JP2004511556A5 (enExample) | ||
| CA2472149A1 (en) | New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments | |
| CA2471578A1 (en) | Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments | |
| RU2004126441A (ru) | Новые антихолинергические средства, способ их получения, а также их применение в качестве лекарственных средств | |
| JP7074903B2 (ja) | イミダゾピリダジン化合物 | |
| JP2009542613A5 (enExample) | ||
| JP2021105002A5 (enExample) | ||
| US20140235612A1 (en) | Azabenzimidazole Compounds | |
| JP5331688B2 (ja) | Ｍ３アンタゴニストとしてのキヌクリジン誘導体 | |
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2009534368A5 (enExample) | ||
| JP2020510010A5 (enExample) | ||
| HU228594B1 (en) | Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same | |
| JP2012521994A5 (enExample) | ||
| JP2005519908A5 (enExample) | ||
| JP2008509187A5 (enExample) | ||
| JP2010513434A5 (enExample) | ||
| JP2001510843A5 (enExample) | ||
| JP2010505961A5 (enExample) | ||
| JP2007522162A5 (enExample) | ||
| CA3015166A1 (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| JP2003529597A5 (enExample) |